Immunotherapy Drugs: Global Markets
Report Scope:
The global immunotherapy market can be segmented into the following types: checkpoint inhibitors, monoclonal antibodies, interferons and interleukins. This report does not include other immunotherapies such as vaccines and hormones.
The scope of the report includes an overview of the global market and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections.
The report discusses technological, regulatory and economic trends that are affecting the market. It also explains the major drivers and regional dynamics of the global market and current trends within the industry.
Regional analysis includes North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy and Rest of Europe), Asia-Pacific (China, India, Japan and Rest of Asia-Pacific) and rest of the world (RoW).
Report Includes:
The global immunotherapy market can be segmented into the following types: checkpoint inhibitors, monoclonal antibodies, interferons and interleukins. This report does not include other immunotherapies such as vaccines and hormones.
The scope of the report includes an overview of the global market and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections.
The report discusses technological, regulatory and economic trends that are affecting the market. It also explains the major drivers and regional dynamics of the global market and current trends within the industry.
Regional analysis includes North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy and Rest of Europe), Asia-Pacific (China, India, Japan and Rest of Asia-Pacific) and rest of the world (RoW).
Report Includes:
- 20 data tables and 26 additional tables
- An overview of the global market for immunotherapy drugs
- Estimation of the market size and analyses of global market trends, with data from 2019, 2020, and projections of compound annual growth rates (CAGRs) though 2025
- Evaluation of current market size and forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth
- Description of immunotherapy, combination immunotherapy and discussion on how it targets on cell-mediated adaptive immunity
- Market share analysis of the immunotherapy drugs based on type of drug, therapy area, end user and region
- Information on personalized treatment paradigm, details of clinically significant types of cancers and discussion on future of immunotherapy in cancer
- Details of checkpoint inhibitors, monoclonal antibodies, interleukins and interferons; and coverage of innovative strategies and novel targeted approaches for immunotherapy
- Discussion on fine tuning versus boosting cancer immunity and early versus advanced stage cancer immunotherapy
- Market share analysis of the major players in the industry, and discussion on their technological strengths and weakness, and innovative marketing practices
- Comprehensive company profiles of major players of the industry, including Amgen Inc., Bayer AG, Johnson & Johnson, Novartis AG and Pfizer Inc.
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Scope of Report
Methodology
Market Estimates
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Immunotherapy
Towards Combination Immunotherapy
Focusing on Cell-mediated Adaptive Immunity
Fine Tuning Vs. Boosting Cancer Immunity
Early Vs. Advanced Stage Cancer Immunotherapy
Personalized Treatment Paradigm
Clinically Significant Types of Cancers
Lung Cancer
Breast Cancer
Colorectal Cancer
Stomach Cancer
Leukemia
Future of Immunotherapy in Cancer
Infectious Diseases
Immunotherapy against Autoimmune Disorders
Immunotherapies against Infectious Diseases
Biologics as Autoimmune Disorder Therapies
Trends in Autoimmune Disorder Therapies
Types of Immunotherapies
Checkpoint Inhibitors
Unmet Medical Needs
New Biomarkers to Stratify Patients
Relapse/Refractory Patients
Treatment Efficacy and Tolerability
Innovative Strategies
Novel Targeted Approaches
Monoclonal Antibodies
Interleukins
Interferons
CHAPTER 4 MARKET DYNAMICS
Strengths of Immunotherapy Market
Growing Aging Population
Rising Incidence of Diseases
Patent Expirations
Growing Pipeline
Drive to Reduce Costs
Government Incentives
Collaborations and Partnerships
Mergers and Acquisitions
Weaknesses of the Immunotherapy Market
Manufacturing Process
Process Definition and Testing and Validation
Lack of Skilled Personnel
Regulatory Guidelines
Patent Litigation
Threats to Immunotherapy Market
Unpredictable Regulatory Landscape
Prescriptions by Medical Practitioners/Pharmacies
Competition
Opportunities in the Immunotherapy Market
Emerging Markets
Technological Innovation and Improved Process Knowledge
Pricing
CHAPTER 5 IMPACT OF COVID-19 ON THE PHARMACEUTICAL INDUSTRY
Short-term Impact
Change in Demand
Shift of Communication and Promotions to Remote Interactions
Changes to R&D
Long-term Impact
Delayed Approvals for Non-COVID-related Pharmaceutical Products
Self-sufficiency in the Pharmaceutical Industry
Changes in Consumption Trends in Health-related Products
CHAPTER 6 MARKET BREAKDOWN BY PRODUCT TYPE
Overview
Monoclonal Antibodies
Market Overview
Market Revenue
Market Share
Market by Region
Market Overview
Market Revenue
Market Share
Checkpoint Inhibitors
Pembrolizumab
Companion Diagnostic
Clinical Trial Program
Forecast for Pembrolizumab
Nivolumab (Opdivo)
Companion Diagnostic
Clinical Trial Program
Forecast for Nivolumab
Atezolizumab (Tecentriq)
Companion Diagnostic
Clinical Trial Program
Forecast for Atezolizumab
Avelumab (Bavencio)
Companion Diagnostic
Clinical Trial Program
Forecast for Avelumab
Durvalumab (Imfinzi)
Companion Diagnostic
Clinical Trial Program
Durvalumab Forecasts
Yervoy (Ipilimumab)
Market by Region
Market Revenue
Market Share
Interferons and Interleukins
Market Revenue
Market by Region
Market by Disease Area
CHAPTER 7 MARKET BREAKDOWN BY REGION
Market Overview and Discussion
North America
United States
Canada
Europe
Asia-Pacific
China
Japan
Rest of the World
CHAPTER 8 COMPANY PROFILES
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL MYERS SQUIBB
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON
VIATRIS INC. (FORMERLY MYLAN)
NOVARTIS AG
PFIZER INC.
VERTEX PHARMACEUTICALS INC.
Study Goals and Objectives
Scope of Report
Methodology
Market Estimates
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Immunotherapy
Towards Combination Immunotherapy
Focusing on Cell-mediated Adaptive Immunity
Fine Tuning Vs. Boosting Cancer Immunity
Early Vs. Advanced Stage Cancer Immunotherapy
Personalized Treatment Paradigm
Clinically Significant Types of Cancers
Lung Cancer
Breast Cancer
Colorectal Cancer
Stomach Cancer
Leukemia
Future of Immunotherapy in Cancer
Infectious Diseases
Immunotherapy against Autoimmune Disorders
Immunotherapies against Infectious Diseases
Biologics as Autoimmune Disorder Therapies
Trends in Autoimmune Disorder Therapies
Types of Immunotherapies
Checkpoint Inhibitors
Unmet Medical Needs
New Biomarkers to Stratify Patients
Relapse/Refractory Patients
Treatment Efficacy and Tolerability
Innovative Strategies
Novel Targeted Approaches
Monoclonal Antibodies
Interleukins
Interferons
CHAPTER 4 MARKET DYNAMICS
Strengths of Immunotherapy Market
Growing Aging Population
Rising Incidence of Diseases
Patent Expirations
Growing Pipeline
Drive to Reduce Costs
Government Incentives
Collaborations and Partnerships
Mergers and Acquisitions
Weaknesses of the Immunotherapy Market
Manufacturing Process
Process Definition and Testing and Validation
Lack of Skilled Personnel
Regulatory Guidelines
Patent Litigation
Threats to Immunotherapy Market
Unpredictable Regulatory Landscape
Prescriptions by Medical Practitioners/Pharmacies
Competition
Opportunities in the Immunotherapy Market
Emerging Markets
Technological Innovation and Improved Process Knowledge
Pricing
CHAPTER 5 IMPACT OF COVID-19 ON THE PHARMACEUTICAL INDUSTRY
Short-term Impact
Change in Demand
Shift of Communication and Promotions to Remote Interactions
Changes to R&D
Long-term Impact
Delayed Approvals for Non-COVID-related Pharmaceutical Products
Self-sufficiency in the Pharmaceutical Industry
Changes in Consumption Trends in Health-related Products
CHAPTER 6 MARKET BREAKDOWN BY PRODUCT TYPE
Overview
Monoclonal Antibodies
Market Overview
Market Revenue
Market Share
Market by Region
Market Overview
Market Revenue
Market Share
Checkpoint Inhibitors
Pembrolizumab
Companion Diagnostic
Clinical Trial Program
Forecast for Pembrolizumab
Nivolumab (Opdivo)
Companion Diagnostic
Clinical Trial Program
Forecast for Nivolumab
Atezolizumab (Tecentriq)
Companion Diagnostic
Clinical Trial Program
Forecast for Atezolizumab
Avelumab (Bavencio)
Companion Diagnostic
Clinical Trial Program
Forecast for Avelumab
Durvalumab (Imfinzi)
Companion Diagnostic
Clinical Trial Program
Durvalumab Forecasts
Yervoy (Ipilimumab)
Market by Region
Market Revenue
Market Share
Interferons and Interleukins
Market Revenue
Market by Region
Market by Disease Area
CHAPTER 7 MARKET BREAKDOWN BY REGION
Market Overview and Discussion
North America
United States
Canada
Europe
Asia-Pacific
China
Japan
Rest of the World
CHAPTER 8 COMPANY PROFILES
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL MYERS SQUIBB
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON
VIATRIS INC. (FORMERLY MYLAN)
NOVARTIS AG
PFIZER INC.
VERTEX PHARMACEUTICALS INC.
LIST OF TABLES
Summary Table B: Global Market for Immunotherapy Drugs, by Region, Through 2025
Summary Table A: Global Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 1: Stages of Lung Cancer
Table 2: Biologics as Autoimmune Disorder Therapies
Table 3: Adverse Events Associated with Immune-Checkpoint Blockade
Table 4: Evolution of Monoclonal Antibodies
Table 5: Advantages and Disadvantages of Monoclonal Antibodies
Table 6: Murine Monoclonal Antibodies
Table 7: Chimeric Monoclonal Antibodies
Table 8: Humanized Monoclonal Antibodies
Table 9: Human Monoclonal Antibodies
Table 10: Selected Approved Interferon Alpha Analogs
Table 11: Global Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 12: Global Market for Monoclonal Antibodies, by Type, Through 2025
Table 13: Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019
Table 14: Global Market for Monoclonal Antibody Drugs, by Region, Through 2025
Table 15: Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019
Table 16: Global Market for Checkpoint Inhibitors, 2019-2025
Table 17: Pembrolizumab Approved Indications
Table 18: Nivolumab Approved Indications
Table 19: Atezolizumab Approved Indications
Table 20: Avelumab Approved Indications
Table 21: Durvalumab Approved Indications
Table 22: Global Market of Checkpoint Inhibitors, by Region, Through 2025
Table 23: Global Market Shares for Checkpoint Inhibitors, by Region, 2019
Table 24: Global Market for Interferons and Interleukins, Through 2025
Table 25: Global Market for Interferons and Interleukins, by Region, Through 2025
Table 26: Global Market for Immunotherapy, by Therapeutic Area, Through 2025
Table 27: Global Market for Immunotherapy Drugs, by Region, Through 2025
Table 28: North American Market for Immunotherapy Drugs, by Country, Through 2025
Table 29: North American Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 30: European Market for Immunotherapy Drugs, by Country, Through 2025
Table 31: European Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 32: Asia-Pacific Market for Immunotherapy Drugs, by Country, Through 2025
Table 33: Asia-Pacific Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 34: Chinese Market Statistics
Table 35: Japanese Market Statistics
Table 36: AbbVie: Product Portfolio
Table 37: Amgen: Product Portfolio
Table 38: AstraZeneca: Product Portfolio
Table 39: Bayer AG: Product Portfolio
Table 40: Johnson & Johnson: Product Portfolio
Table 41: Viatris: Product Portfolio
Table 42: Novartis AG: Product Portfolio
Table 43: Pfizer: Product Portfolio
Table 44: Pfizer: Pipeline Product Portfolio
Summary Table B: Global Market for Immunotherapy Drugs, by Region, Through 2025
Summary Table A: Global Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 1: Stages of Lung Cancer
Table 2: Biologics as Autoimmune Disorder Therapies
Table 3: Adverse Events Associated with Immune-Checkpoint Blockade
Table 4: Evolution of Monoclonal Antibodies
Table 5: Advantages and Disadvantages of Monoclonal Antibodies
Table 6: Murine Monoclonal Antibodies
Table 7: Chimeric Monoclonal Antibodies
Table 8: Humanized Monoclonal Antibodies
Table 9: Human Monoclonal Antibodies
Table 10: Selected Approved Interferon Alpha Analogs
Table 11: Global Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 12: Global Market for Monoclonal Antibodies, by Type, Through 2025
Table 13: Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019
Table 14: Global Market for Monoclonal Antibody Drugs, by Region, Through 2025
Table 15: Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019
Table 16: Global Market for Checkpoint Inhibitors, 2019-2025
Table 17: Pembrolizumab Approved Indications
Table 18: Nivolumab Approved Indications
Table 19: Atezolizumab Approved Indications
Table 20: Avelumab Approved Indications
Table 21: Durvalumab Approved Indications
Table 22: Global Market of Checkpoint Inhibitors, by Region, Through 2025
Table 23: Global Market Shares for Checkpoint Inhibitors, by Region, 2019
Table 24: Global Market for Interferons and Interleukins, Through 2025
Table 25: Global Market for Interferons and Interleukins, by Region, Through 2025
Table 26: Global Market for Immunotherapy, by Therapeutic Area, Through 2025
Table 27: Global Market for Immunotherapy Drugs, by Region, Through 2025
Table 28: North American Market for Immunotherapy Drugs, by Country, Through 2025
Table 29: North American Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 30: European Market for Immunotherapy Drugs, by Country, Through 2025
Table 31: European Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 32: Asia-Pacific Market for Immunotherapy Drugs, by Country, Through 2025
Table 33: Asia-Pacific Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 34: Chinese Market Statistics
Table 35: Japanese Market Statistics
Table 36: AbbVie: Product Portfolio
Table 37: Amgen: Product Portfolio
Table 38: AstraZeneca: Product Portfolio
Table 39: Bayer AG: Product Portfolio
Table 40: Johnson & Johnson: Product Portfolio
Table 41: Viatris: Product Portfolio
Table 42: Novartis AG: Product Portfolio
Table 43: Pfizer: Product Portfolio
Table 44: Pfizer: Pipeline Product Portfolio
LIST OF FIGURES
Summary Figure A: Global Market for Immunotherapy Drugs, by Product Type, 2019-2025
Summary Figure B: Global Market for Immunotherapy Drugs, by Region, 2019-2025
Figure 1: Annual Incidence and Mortality Data for Lung Cancer in the U.S., 1990-2020
Figure 2: Annual Incidence and Mortality Data for Lung Cancer in Five EU Countries, 1975-2020
Figure 3: Annual Incidence and Mortality Data for Lung Cancer in the Rest of the World, 1975-2020
Figure 4: Five-Year Survival Rates, by Lung Cancer Stage
Figure 5: Annual Incidence and Mortality Data for Breast Cancer in the U.S., 1975-2020
Figure 6: Annual Incidence and Mortality Data for Breast Cancer in Five E.U. Countries., 1975-2020
Figure 7: Annual Incidence and Mortality Data for Breast Cancer in Japan, 1975-2020
Figure 8: Annual Incidence and Mortality Data for Breast Cancer in the Rest of the World, 1975-2020
Figure 9: Five-Year Survival Rates, by Breast Cancer Stage
Figure 10: Annual Incidence and Mortality Data for Colorectal Cancer in the U.S., 1975-2020
Figure 11: Annual Incidence and Mortality Data for Colorectal Cancer in Five EU Countries, 1975-2020
Figure 12: Annual Incidence and Mortality Data for Colorectal Cancer in Japan, 1975-2020
Figure 13: Annual Incidence and Mortality Data for Colorectal Cancer in the Rest of the World, 1975-2020
Figure 14: Five-Year Survival Rates, by Colorectal Cancer Stage
Figure 15: Annual Incidence and Mortality Data for Stomach Cancer in the U.S., 1975-2020
Figure 16: Annual Incidence and Mortality Data for Stomach Cancer in Five EU Countries, 1975-2012
Figure 17: Annual Incidence and Mortality Data for Stomach Cancer in Japan, 1975-2020
Figure 18: Annual Incidence and Mortality Data for Stomach Cancer in the Rest of the World, 1975-2020
Figure 19: Five-Year Survival Rates, by Stomach Cancer Stage
Figure 20: Annual Incidence and Mortality Data for Leukemia in the U.S., 1975-2020
Figure 21: Annual Incidence and Mortality Data for Leukemia in Five EU Countries, 1975-2020
Figure 22: Annual Incidence and Mortality Data for Leukemia in Japan, 1975-2020
Figure 23: Annual Incidence and Mortality Data for Leukemia in the Rest of the World, 1975-2020
Figure 24: Potential Targets for Checkpoint Inhibition in Clinical Evaluation
Figure 25: SWOT Analysis of Immunotherapy Market
Figure 26: Impact of COVID-19 on the Pharmaceutical Industry
Figure 27: Global Market for Immunotherapy Drugs, 2019-2025
Figure 28: Global Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 29: Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019
Figure 30: Global Market for Monoclonal Antibody Drugs, by Region, 2019-2025
Figure 31: Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019
Figure 32: Pembrolizumab Comprehensive Clinical Trial Programs, by Status
Figure 33: Pembrolizumab Comprehensive Clinical Trial Programs, by Therapy
Figure 34: Pembrolizumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 35: Global Market for Pembrolizumab, 2019-2025
Figure 36: Nivolumab Comprehensive Clinical Trial Programs, by Status
Figure 37: Nivolumab Comprehensive Clinical Trial Programs, by Therapy
Figure 38: Nivolumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 39: Global Market for Nivolumab, 2019-2025
Figure 40: Atezolizumab Comprehensive Clinical Trial Programs, by Status
Figure 41: Atezolizumab Comprehensive Clinical Trial Programs, by Therapy
Figure 42: Atezolizumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 43: Global Market for Atezolizumab, 2019-2025
Figure 44: Avelumab Comprehensive Clinical Trial Programs, by Status
Figure 45: Avelumab Comprehensive Clinical Trial Programs, by Therapy
Figure 46: Avelumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 47: Global Market for Avelumab, 2019-2025
Figure 48: Durvalumab Comprehensive Clinical Trial Programs, by Status
Figure 49: Durvalumab Comprehensive Clinical Trial Programs, by Therapy
Figure 50: Durvalumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 51: Global Market for Durvalumab, 2019-2025
Figure 52: Global Market for Ipilimumab, 2019-2025
Figure 53: Global Market for Checkpoint Inhibitors, by Region, 2019-2025
Figure 54: Global Market Shares for Checkpoint Inhibitors, by Region, 2019
Figure 55: Global Market for Interferons and Interleukins, by Region, 2019-2025
Figure 56: Global Market Shares for Immunotherapy Drugs, by Region, 2019
Figure 57: North American Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 58: European Market for Immunotherapy Drugs, by Country, 2019-2025
Figure 59: European Market for Immunotherapy Drugs, by Product Type, 2019-2025
Figure 60: Asia-Pacific Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 61: AbbVie Inc.: Annual Revenue, 2016-2019
Figure 62: AbbVie: Revenue Share, by Region/Country, 2019
Figure 63: AbbVie: Revenue Share, by Business Unit, 2019
Figure 64: Amgen: Annual Revenue, 2016-2019
Figure 65: Amgen: Revenue Share, by Region/Country, 2019
Figure 66: Amgen: Revenue Share, by Products, 2019
Figure 67: AstraZeneca: Annual Revenue, 2016-2019
Figure 68: AstraZeneca: Revenue Share, by Region/Country, 2019
Figure 69: AstraZeneca: Revenue Share, by Business Unit, 2019
Figure 70: Bayer AG: Annual Revenue, 2016-2019
Figure 71: Bayer AG: Revenue Share, by Region, 2019
Figure 72: Bayer AG: Revenue Share, by Business Unit, 2019
Figure 73: Bristol Myers Squibb: Annual Revenue, 2016-2019
Figure 74: Bristol Myers Squibb: Revenue Share, by Region/Country, 2019
Figure 75: Bristol Myers Squibb: Revenue Share, by Brands, 2019
Figure 76: Hoffmann-La Roche: Annual Revenue, 2016-2019
Figure 77: Hoffmann-La Roche: Revenue Share in Pharmaceutical Segment, by Region/Country, 2019
Figure 78: Hoffmann-La Roche: Revenue Share, by Business Segment, 2019
Figure 79: Johnson & Johnson: Annual Revenue, 2016-2019
Figure 80: Johnson & Johnson: Revenue Share, by Region/Country, 2019
Figure 81: Johnson & Johnson: Revenue Share, by Business Unit, 2019
Figure 82: Viatris: Annual Revenue, 2016-2019
Figure 83: Viatris: Revenue Share, by Region, 2019
Figure 84: Viatris: Revenue Share, by Business Unit, 2019
Figure 85: Novartis AG: Annual Revenue, 2015-2019
Figure 86: Novartis AG: Revenue Share, by Region/Country, 2019
Figure 87: Novartis AG: Revenue Share, by Business Segment, 2019
Figure 88: Pfizer: Annual Revenue, 2016-2019
Figure 89: Pfizer: Revenue Share, by Region/Country, 2019
Figure 90: Pfizer: Revenue Share, by Business Segment, 2019
Figure 91: Vertex Pharmaceuticals: Annual Revenue, 2016-2019
Figure 92: Vertex Pharmaceuticals: R&D Expense Annual Revenue, 2017-2019
Figure 93: Vertex Pharmaceuticals: Revenue Share, by Business Segment, 2019
Summary Figure A: Global Market for Immunotherapy Drugs, by Product Type, 2019-2025
Summary Figure B: Global Market for Immunotherapy Drugs, by Region, 2019-2025
Figure 1: Annual Incidence and Mortality Data for Lung Cancer in the U.S., 1990-2020
Figure 2: Annual Incidence and Mortality Data for Lung Cancer in Five EU Countries, 1975-2020
Figure 3: Annual Incidence and Mortality Data for Lung Cancer in the Rest of the World, 1975-2020
Figure 4: Five-Year Survival Rates, by Lung Cancer Stage
Figure 5: Annual Incidence and Mortality Data for Breast Cancer in the U.S., 1975-2020
Figure 6: Annual Incidence and Mortality Data for Breast Cancer in Five E.U. Countries., 1975-2020
Figure 7: Annual Incidence and Mortality Data for Breast Cancer in Japan, 1975-2020
Figure 8: Annual Incidence and Mortality Data for Breast Cancer in the Rest of the World, 1975-2020
Figure 9: Five-Year Survival Rates, by Breast Cancer Stage
Figure 10: Annual Incidence and Mortality Data for Colorectal Cancer in the U.S., 1975-2020
Figure 11: Annual Incidence and Mortality Data for Colorectal Cancer in Five EU Countries, 1975-2020
Figure 12: Annual Incidence and Mortality Data for Colorectal Cancer in Japan, 1975-2020
Figure 13: Annual Incidence and Mortality Data for Colorectal Cancer in the Rest of the World, 1975-2020
Figure 14: Five-Year Survival Rates, by Colorectal Cancer Stage
Figure 15: Annual Incidence and Mortality Data for Stomach Cancer in the U.S., 1975-2020
Figure 16: Annual Incidence and Mortality Data for Stomach Cancer in Five EU Countries, 1975-2012
Figure 17: Annual Incidence and Mortality Data for Stomach Cancer in Japan, 1975-2020
Figure 18: Annual Incidence and Mortality Data for Stomach Cancer in the Rest of the World, 1975-2020
Figure 19: Five-Year Survival Rates, by Stomach Cancer Stage
Figure 20: Annual Incidence and Mortality Data for Leukemia in the U.S., 1975-2020
Figure 21: Annual Incidence and Mortality Data for Leukemia in Five EU Countries, 1975-2020
Figure 22: Annual Incidence and Mortality Data for Leukemia in Japan, 1975-2020
Figure 23: Annual Incidence and Mortality Data for Leukemia in the Rest of the World, 1975-2020
Figure 24: Potential Targets for Checkpoint Inhibition in Clinical Evaluation
Figure 25: SWOT Analysis of Immunotherapy Market
Figure 26: Impact of COVID-19 on the Pharmaceutical Industry
Figure 27: Global Market for Immunotherapy Drugs, 2019-2025
Figure 28: Global Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 29: Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019
Figure 30: Global Market for Monoclonal Antibody Drugs, by Region, 2019-2025
Figure 31: Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019
Figure 32: Pembrolizumab Comprehensive Clinical Trial Programs, by Status
Figure 33: Pembrolizumab Comprehensive Clinical Trial Programs, by Therapy
Figure 34: Pembrolizumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 35: Global Market for Pembrolizumab, 2019-2025
Figure 36: Nivolumab Comprehensive Clinical Trial Programs, by Status
Figure 37: Nivolumab Comprehensive Clinical Trial Programs, by Therapy
Figure 38: Nivolumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 39: Global Market for Nivolumab, 2019-2025
Figure 40: Atezolizumab Comprehensive Clinical Trial Programs, by Status
Figure 41: Atezolizumab Comprehensive Clinical Trial Programs, by Therapy
Figure 42: Atezolizumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 43: Global Market for Atezolizumab, 2019-2025
Figure 44: Avelumab Comprehensive Clinical Trial Programs, by Status
Figure 45: Avelumab Comprehensive Clinical Trial Programs, by Therapy
Figure 46: Avelumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 47: Global Market for Avelumab, 2019-2025
Figure 48: Durvalumab Comprehensive Clinical Trial Programs, by Status
Figure 49: Durvalumab Comprehensive Clinical Trial Programs, by Therapy
Figure 50: Durvalumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 51: Global Market for Durvalumab, 2019-2025
Figure 52: Global Market for Ipilimumab, 2019-2025
Figure 53: Global Market for Checkpoint Inhibitors, by Region, 2019-2025
Figure 54: Global Market Shares for Checkpoint Inhibitors, by Region, 2019
Figure 55: Global Market for Interferons and Interleukins, by Region, 2019-2025
Figure 56: Global Market Shares for Immunotherapy Drugs, by Region, 2019
Figure 57: North American Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 58: European Market for Immunotherapy Drugs, by Country, 2019-2025
Figure 59: European Market for Immunotherapy Drugs, by Product Type, 2019-2025
Figure 60: Asia-Pacific Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 61: AbbVie Inc.: Annual Revenue, 2016-2019
Figure 62: AbbVie: Revenue Share, by Region/Country, 2019
Figure 63: AbbVie: Revenue Share, by Business Unit, 2019
Figure 64: Amgen: Annual Revenue, 2016-2019
Figure 65: Amgen: Revenue Share, by Region/Country, 2019
Figure 66: Amgen: Revenue Share, by Products, 2019
Figure 67: AstraZeneca: Annual Revenue, 2016-2019
Figure 68: AstraZeneca: Revenue Share, by Region/Country, 2019
Figure 69: AstraZeneca: Revenue Share, by Business Unit, 2019
Figure 70: Bayer AG: Annual Revenue, 2016-2019
Figure 71: Bayer AG: Revenue Share, by Region, 2019
Figure 72: Bayer AG: Revenue Share, by Business Unit, 2019
Figure 73: Bristol Myers Squibb: Annual Revenue, 2016-2019
Figure 74: Bristol Myers Squibb: Revenue Share, by Region/Country, 2019
Figure 75: Bristol Myers Squibb: Revenue Share, by Brands, 2019
Figure 76: Hoffmann-La Roche: Annual Revenue, 2016-2019
Figure 77: Hoffmann-La Roche: Revenue Share in Pharmaceutical Segment, by Region/Country, 2019
Figure 78: Hoffmann-La Roche: Revenue Share, by Business Segment, 2019
Figure 79: Johnson & Johnson: Annual Revenue, 2016-2019
Figure 80: Johnson & Johnson: Revenue Share, by Region/Country, 2019
Figure 81: Johnson & Johnson: Revenue Share, by Business Unit, 2019
Figure 82: Viatris: Annual Revenue, 2016-2019
Figure 83: Viatris: Revenue Share, by Region, 2019
Figure 84: Viatris: Revenue Share, by Business Unit, 2019
Figure 85: Novartis AG: Annual Revenue, 2015-2019
Figure 86: Novartis AG: Revenue Share, by Region/Country, 2019
Figure 87: Novartis AG: Revenue Share, by Business Segment, 2019
Figure 88: Pfizer: Annual Revenue, 2016-2019
Figure 89: Pfizer: Revenue Share, by Region/Country, 2019
Figure 90: Pfizer: Revenue Share, by Business Segment, 2019
Figure 91: Vertex Pharmaceuticals: Annual Revenue, 2016-2019
Figure 92: Vertex Pharmaceuticals: R&D Expense Annual Revenue, 2017-2019
Figure 93: Vertex Pharmaceuticals: Revenue Share, by Business Segment, 2019
